-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the latest data from Minet.
com, the sales of proprietary Chinese medicines in the terminal digestive system of physical pharmacies in cities in China will exceed 14 billion yuan in 2020, and it is expected to reach a new high in 2021
.
From the perspective of sub-categories, the five sub-categories of Jianweixiaoshi, Stomach Medicine (Gastritis, Ulcer), and Heat Dispelling Medicine are the best sellers, with a total market share of nearly 80%
.
From the perspective of manufacturers, Jiangzhong Pharmaceutical, Taiji Group Chongqing Fuling Pharmaceutical, Zhangzhou Pien Tzehuang Pharmaceutical, Jiangxi Kang Enbei Chinese Medicine, and Mayinglong Pharmaceutical Group rank in the top five
.
Among the TOP20 products, 11 are exclusive products; the sales of Jianweixiaoshi tablets and Huoxiangzhengqi oral liquid both exceed 1 billion yuan, and Changyanning tablets and Pien Tze Huang are expected to become the next billion-level products
.
Among the TOP20 brands, 18 have sales of more than 100 million yuan
.
Since 2019, only one Chinese patent medicine for the digestive system has been approved for listing.
In addition, two new drugs, namely Liwei Capsules from Jianmin Pharmaceutical Group and Qihuang Capsules from Shandong Phoenix Pharmaceuticals, have submitted marketing applications under review and approval, Zhejiang Jingxin 10 new drugs including Kangfuxin Enteric-coated Capsules from Pharmaceuticals and Cistanche Runtong Oral Liquid from Jiangsu Kangyuan Pharmaceuticals | Beijing Huayi Shennong Pharmaceutical have been approved for clinical use
.
New high! Jiangzhong and Taiji "lead" the tens of billions market in recent years, the sales of proprietary Chinese medicines in the terminal digestive system of physical pharmacies in Chinese cities (unit: 100 million yuan) Source: Mi Nei.
com.
The latest data from Mi Nei.
com shows that Chinese urban entities in recent years The market for proprietary Chinese medicines in the terminal digestive system of pharmacies has maintained steady growth, with sales exceeding 14 billion yuan in 2020, and is expected to reach a new high in 2021, a year-on-year increase of 3.
11%
.
In recent years, the top 5 sub-categories of digestive system proprietary Chinese medicines in Chinese urban physical pharmacies.
Source: Meinenet.
com.
Chinese city physical pharmacies terminal competition pattern.
Among the 13 sub-categories of digestive system proprietary Chinese medicines, stomach medicines (gastritis, ulcers), and anticancer drugs The five sub-categories of Shuji, liver disease drugs, and hemorrhoid drugs are the best sellers, with a total market share of nearly 80%
.
It is worth noting that for many years, stomach medicines (gastritis, ulcers) have been the largest sub-category of Chinese patent medicines for the digestive system.
.
2021E China's urban entity pharmacy terminal digestive system TCM manufacturers TOP3 Source: Meinenet.
China's urban entity pharmacy terminal competition pattern.
From the perspective of manufacturers, Jiangzhong Pharmaceutical, Taiji Group Chongqing Fuling Pharmaceutical, Zhangzhou Pien Tze Huang Pharmaceutical, Jiangxi Kang Enbei Chinese Medicine , Ma Yinglong Pharmaceutical Group ranks firmly in the top five
.
The third one billion Chinese patent medicine for the digestive system may be born! The TOP20 ranking has changed, and 11 exclusive products are dazzling.
In 2021E, the top 20 proprietary Chinese medicine products in the terminal digestive system of physical pharmacies in Chinese cities (unit: 100 million yuan) Source: Mynet.
com.
Among them, Jianweixiaoshi tablets and Huoxiangzhengqi oral liquid both exceeded 1 billion yuan, and Changyanning tablets and Pien Tze Huang are expected to become the next billion-level products by virtue of their steady growth
.
It is worth mentioning that 11 of the TOP20 are exclusive products, involving 10 companies including Zhangzhou Pien Tze Huang Pharmaceutical, Jiangxi Kang Enbei Chinese Medicine, Mayinglong Pharmaceutical Group, and China Resources Sanjiu Pharmaceutical
.
In terms of growth rate, the new compound aloe capsules, Shenling Jianpi Stomach Granules, and Ginseng Jianpi Tablets all exceeded 20%
.
In recent years, Jianwei Xiaoshi Tablets have steadily increased their terminal sales in physical pharmacies in Chinese cities, and are expected to exceed the 1.
5 billion mark in 2021.
At present, there are more than 40 manufacturers of Jianwei Xiaoshi Tablets, of which Jiangzhong Pharmaceutical has the largest market share.
Accounted for more than 90%
.
Jiangzhong Pharmaceutical pointed out in the 2021 semi-annual report that the company will deepen its brand layout and integrate general drug resources in its over-the-counter drug business
.
Among them, the Jiangzhong brand, which clearly uses Jianwei Xiaoshi tablets as a representative product, extends from "stomach" to "spleen", and extends from "daily digestion assistance" to "spleen and stomach digestion" by enriching the spleen and stomach series; restart CCTV advertising Launch, amplify the volume of dissemination, and enhance the potential of the "Jiangzhong" brand
.
Huoxiang Zhengqi Oral Liquid was listed in the ``Diagnosis and Treatment Plan for Pneumonia Caused by New Coronavirus Infection'' by the National Health Commission in 2020.
The fourth to eighth editions are recommended for the treatment of Chinese patent medicines during the medical observation period.
.
According to data from Minai.
com, only two companies of Huoxiang Zhengqi Oral Liquid have production approvals.
In 2020, the terminal sales of physical pharmacies in Chinese cities will exceed 1.
2 billion yuan, and only the Chongqing Fuling Pharmaceutical Factory of Taiji Group will be on sale.
The sales are expected to be in 2021.
Make another record high
.
From the perspective of treatment categories, stomach-invigorating and dispelling drugs and anti-heat agents are the most, with 4 each; followed by stomach medicine (gastritis, ulcer) and hemorrhoids, with 3 each
.
2021E: TOP20 Chinese proprietary Chinese medicine brands in the terminal digestive system of physical pharmacies in cities in China (unit: 100 million yuan) Source: Mi Nei.
com.
Competitive pattern of terminal Chinese city physical pharmacies.
Note: Less than 100 million yuan.
* means that 18 TOP20 brands have sales of more than 100 million yuan.
, Jiangzhong Pharmaceutical's Jianweixiaoshi Tablets, Taiji Group Chongqing Fuling Pharmaceutical's Huoxiangzhengqi Oral Liquid, Jiangxi Kangenbei Chinese Medicine's Changyanning Tablets ranked in the top three
.
In terms of growth rate, Kunming Traditional Chinese Medicine's Shenling Jianpiwei Granule has the fastest growth rate, exceeding 60%; Hebei Wanbang Fulin Pharmaceutical's new compound aloe capsules, exceeding 20%; Jiangxi Kang Enbei Chinese Medicine's Changyanning Tablet, Sichuan Good Doctor Panxi Pharmaceutical's Kangfu New Liquid, Tasly Pharmaceutical Group's Huoxiang Zhengqi Dropping Pills, and Daxing Pharmaceutical's Zhenglu Pills all exceeded 10%
.
Jianmin, Kangyuan, Jingxin.
.
.
12 Class 1 new drugs have launched an impact.
New Chinese patent medicines for the digestive system that have been declared for marketing/clinical since 2019.
Source: Meinenet MED2.
0 China Drug Evaluation Database 2019 to present, digestive system Chinese patent medicines Only Beijing Wuhe Boao Pharmaceutical's Sangzhi total alkaloid tablets have been approved for marketing.
This product is China's first approved new Chinese medicine for diabetes in the past 10 years
.
Two new drugs were submitted for marketing applications and are under review and approval.
Jianmin Pharmaceutical Group’s Liwei Capsule is used for chronic non-atrophic gastritis with erosion and damp-heat stasis syndrome, and Shandong Phoenix Pharmaceutical’s Qihuang Capsule is a new drug for the treatment of diabetic nephropathy
.
In addition, Zhejiang Jingxin Pharmaceutical's Kangfuxin Enteric-coated Capsules, Jiangsu Kangyuan Pharmaceutical | Beijing Huayi Shennong Pharmaceutical's Cistanche Runtong Oral Liquid and other 10 new drugs have been approved for clinical use
.
In terms of subcategories of treatment, diabetes medications, liver disease medications, and stomach medications (gastritis, ulcers) are the most popular
.
Source: Mi Nei.
com database, company announcements, etc.
If there are any errors or omissions, please correct me
.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
com, the sales of proprietary Chinese medicines in the terminal digestive system of physical pharmacies in cities in China will exceed 14 billion yuan in 2020, and it is expected to reach a new high in 2021
.
From the perspective of sub-categories, the five sub-categories of Jianweixiaoshi, Stomach Medicine (Gastritis, Ulcer), and Heat Dispelling Medicine are the best sellers, with a total market share of nearly 80%
.
From the perspective of manufacturers, Jiangzhong Pharmaceutical, Taiji Group Chongqing Fuling Pharmaceutical, Zhangzhou Pien Tzehuang Pharmaceutical, Jiangxi Kang Enbei Chinese Medicine, and Mayinglong Pharmaceutical Group rank in the top five
.
Among the TOP20 products, 11 are exclusive products; the sales of Jianweixiaoshi tablets and Huoxiangzhengqi oral liquid both exceed 1 billion yuan, and Changyanning tablets and Pien Tze Huang are expected to become the next billion-level products
.
Among the TOP20 brands, 18 have sales of more than 100 million yuan
.
Since 2019, only one Chinese patent medicine for the digestive system has been approved for listing.
In addition, two new drugs, namely Liwei Capsules from Jianmin Pharmaceutical Group and Qihuang Capsules from Shandong Phoenix Pharmaceuticals, have submitted marketing applications under review and approval, Zhejiang Jingxin 10 new drugs including Kangfuxin Enteric-coated Capsules from Pharmaceuticals and Cistanche Runtong Oral Liquid from Jiangsu Kangyuan Pharmaceuticals | Beijing Huayi Shennong Pharmaceutical have been approved for clinical use
.
New high! Jiangzhong and Taiji "lead" the tens of billions market in recent years, the sales of proprietary Chinese medicines in the terminal digestive system of physical pharmacies in Chinese cities (unit: 100 million yuan) Source: Mi Nei.
com.
The latest data from Mi Nei.
com shows that Chinese urban entities in recent years The market for proprietary Chinese medicines in the terminal digestive system of pharmacies has maintained steady growth, with sales exceeding 14 billion yuan in 2020, and is expected to reach a new high in 2021, a year-on-year increase of 3.
11%
.
In recent years, the top 5 sub-categories of digestive system proprietary Chinese medicines in Chinese urban physical pharmacies.
Source: Meinenet.
com.
Chinese city physical pharmacies terminal competition pattern.
Among the 13 sub-categories of digestive system proprietary Chinese medicines, stomach medicines (gastritis, ulcers), and anticancer drugs The five sub-categories of Shuji, liver disease drugs, and hemorrhoid drugs are the best sellers, with a total market share of nearly 80%
.
It is worth noting that for many years, stomach medicines (gastritis, ulcers) have been the largest sub-category of Chinese patent medicines for the digestive system.
.
2021E China's urban entity pharmacy terminal digestive system TCM manufacturers TOP3 Source: Meinenet.
China's urban entity pharmacy terminal competition pattern.
From the perspective of manufacturers, Jiangzhong Pharmaceutical, Taiji Group Chongqing Fuling Pharmaceutical, Zhangzhou Pien Tze Huang Pharmaceutical, Jiangxi Kang Enbei Chinese Medicine , Ma Yinglong Pharmaceutical Group ranks firmly in the top five
.
The third one billion Chinese patent medicine for the digestive system may be born! The TOP20 ranking has changed, and 11 exclusive products are dazzling.
In 2021E, the top 20 proprietary Chinese medicine products in the terminal digestive system of physical pharmacies in Chinese cities (unit: 100 million yuan) Source: Mynet.
com.
Among them, Jianweixiaoshi tablets and Huoxiangzhengqi oral liquid both exceeded 1 billion yuan, and Changyanning tablets and Pien Tze Huang are expected to become the next billion-level products by virtue of their steady growth
.
It is worth mentioning that 11 of the TOP20 are exclusive products, involving 10 companies including Zhangzhou Pien Tze Huang Pharmaceutical, Jiangxi Kang Enbei Chinese Medicine, Mayinglong Pharmaceutical Group, and China Resources Sanjiu Pharmaceutical
.
In terms of growth rate, the new compound aloe capsules, Shenling Jianpi Stomach Granules, and Ginseng Jianpi Tablets all exceeded 20%
.
In recent years, Jianwei Xiaoshi Tablets have steadily increased their terminal sales in physical pharmacies in Chinese cities, and are expected to exceed the 1.
5 billion mark in 2021.
At present, there are more than 40 manufacturers of Jianwei Xiaoshi Tablets, of which Jiangzhong Pharmaceutical has the largest market share.
Accounted for more than 90%
.
Jiangzhong Pharmaceutical pointed out in the 2021 semi-annual report that the company will deepen its brand layout and integrate general drug resources in its over-the-counter drug business
.
Among them, the Jiangzhong brand, which clearly uses Jianwei Xiaoshi tablets as a representative product, extends from "stomach" to "spleen", and extends from "daily digestion assistance" to "spleen and stomach digestion" by enriching the spleen and stomach series; restart CCTV advertising Launch, amplify the volume of dissemination, and enhance the potential of the "Jiangzhong" brand
.
Huoxiang Zhengqi Oral Liquid was listed in the ``Diagnosis and Treatment Plan for Pneumonia Caused by New Coronavirus Infection'' by the National Health Commission in 2020.
The fourth to eighth editions are recommended for the treatment of Chinese patent medicines during the medical observation period.
.
According to data from Minai.
com, only two companies of Huoxiang Zhengqi Oral Liquid have production approvals.
In 2020, the terminal sales of physical pharmacies in Chinese cities will exceed 1.
2 billion yuan, and only the Chongqing Fuling Pharmaceutical Factory of Taiji Group will be on sale.
The sales are expected to be in 2021.
Make another record high
.
From the perspective of treatment categories, stomach-invigorating and dispelling drugs and anti-heat agents are the most, with 4 each; followed by stomach medicine (gastritis, ulcer) and hemorrhoids, with 3 each
.
2021E: TOP20 Chinese proprietary Chinese medicine brands in the terminal digestive system of physical pharmacies in cities in China (unit: 100 million yuan) Source: Mi Nei.
com.
Competitive pattern of terminal Chinese city physical pharmacies.
Note: Less than 100 million yuan.
* means that 18 TOP20 brands have sales of more than 100 million yuan.
, Jiangzhong Pharmaceutical's Jianweixiaoshi Tablets, Taiji Group Chongqing Fuling Pharmaceutical's Huoxiangzhengqi Oral Liquid, Jiangxi Kangenbei Chinese Medicine's Changyanning Tablets ranked in the top three
.
In terms of growth rate, Kunming Traditional Chinese Medicine's Shenling Jianpiwei Granule has the fastest growth rate, exceeding 60%; Hebei Wanbang Fulin Pharmaceutical's new compound aloe capsules, exceeding 20%; Jiangxi Kang Enbei Chinese Medicine's Changyanning Tablet, Sichuan Good Doctor Panxi Pharmaceutical's Kangfu New Liquid, Tasly Pharmaceutical Group's Huoxiang Zhengqi Dropping Pills, and Daxing Pharmaceutical's Zhenglu Pills all exceeded 10%
.
Jianmin, Kangyuan, Jingxin.
.
.
12 Class 1 new drugs have launched an impact.
New Chinese patent medicines for the digestive system that have been declared for marketing/clinical since 2019.
Source: Meinenet MED2.
0 China Drug Evaluation Database 2019 to present, digestive system Chinese patent medicines Only Beijing Wuhe Boao Pharmaceutical's Sangzhi total alkaloid tablets have been approved for marketing.
This product is China's first approved new Chinese medicine for diabetes in the past 10 years
.
Two new drugs were submitted for marketing applications and are under review and approval.
Jianmin Pharmaceutical Group’s Liwei Capsule is used for chronic non-atrophic gastritis with erosion and damp-heat stasis syndrome, and Shandong Phoenix Pharmaceutical’s Qihuang Capsule is a new drug for the treatment of diabetic nephropathy
.
In addition, Zhejiang Jingxin Pharmaceutical's Kangfuxin Enteric-coated Capsules, Jiangsu Kangyuan Pharmaceutical | Beijing Huayi Shennong Pharmaceutical's Cistanche Runtong Oral Liquid and other 10 new drugs have been approved for clinical use
.
In terms of subcategories of treatment, diabetes medications, liver disease medications, and stomach medications (gastritis, ulcers) are the most popular
.
Source: Mi Nei.
com database, company announcements, etc.
If there are any errors or omissions, please correct me
.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
